Botulinum neurotoxin 3D structures
3D structures of botulinum neurotoxin3D structures of botulinum neurotoxin
Updated on 10-December-2024
{"openlevels":0}
- Type A
- Type A Light Chain residues 1-425
- 2g7k, 2g7p, 2g7q, 2imc, 3bwi, 3bon, 3qix, 2ise, 2isg, 2ish, 4ej5, 7ky2, 7kyf, 7kyh - CbCBN LC + Zn
- 5vgv - CbCBN LC + Cu
- 5vgx - CbCBN LC + Hg
- 3bok - CbCBN LC
- 1e1h, 1xtf, 4kuf, 4el4, 4elc - CbCBN LC (mutant) + Zn
- 3dse – CbCBN LC (mutant) + Zn + Ni
- 1xtg - CbCBN LC (mutant) + synaptosomal-associated protein 25 + Zn
- 3dda, 3ddb - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn
- 3zur, 3zus - CbCBN LC/synaptosomal-associated protein 25 translocation domain
- 2g7n, 2ilp, 2imb, 3qiy, 3qiz, 3qj0, 4hev, 2ima, 5v8r, 6xcb, 6xcc, 6xce, 6xcf, 7n18 – CbCBN LC + inhibitor + Zn
- 3c88, 3c89, 3c8a, 3c8b, 3boo, 3qw5, 3qw6, 3qw7, 3qw8, 3nf3 – CbCBN LC + inhibitor peptide + Zn
- 4ks6, 4ktx, 5v8p, 5v8u - CbCBN LC (mutant) + inhibitor peptide + Zn
- 3ds9 – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni
- 3k3q - CbCBN LC + antibody + Zn
- 7l6v, 7lzp, 7m1h - CbCBN LC + nanobody + Zn
- 2g7k, 2g7p, 2g7q, 2imc, 3bwi, 3bon, 3qix, 2ise, 2isg, 2ish, 4ej5, 7ky2, 7kyf, 7kyh - CbCBN LC + Zn
- Type A translocation domain residues 547-871
- Type A receptor-binding or heavy chain domain residues 871-1296
- 2vua, 3fuo, 5tpb, 5tpc, 5lr0, 5mk6, 5mk7, 6f0o, 6f0p, 6twp, 6two, [7dvl]], 7z5t, 8alp – CbPBN
- 4iqp – CbPBN (mutant)
- 7qpt, 7qpu, 7z5s, 8agk – CbPBN + oligosaccharide
- 2vu9 – CbPBN + polysaccharide + Mg
- 8jle, 8jlf, 8jlg – CbCBN + synaptic vesicle glycoprotein 2A – Cryo EM
- 8jlh, 8js8, 8k77 – CbCBN + synaptic vesicle glycoprotein 2A + drug – Cryo EM
- 4jra, 5jlv, 5moy, 6es1 – CbCBN + synaptic vesicle glycoprotein 2C
- 5jmc – CbCBN (mutant) + synaptic vesicle glycoprotein 2C
- 4zjx – CbCBN + polypeptide inhibitor
- 5l21 – CbCBN + VHH-C2
- 2vua, 3fuo, 5tpb, 5tpc, 5lr0, 5mk6, 5mk7, 6f0o, 6f0p, 6twp, 6two, [7dvl]], 7z5t, 8alp – CbPBN
- Type A Light+Heavy Chain translocation domain residues 1-877
- Type B residues 1-1291
- 7qfq – CbCBN (mutant) – Cryo EM
- 1s0b, 1s0c, 1s0d, 1s0e, 1s0f, 1s0g, 1epw – CbCBN + Zn
- 6g5f – CbCBN + synaptotagmin-1
- 2np0 – CbCBN + synaptotagmin-2 + Zn
- 6g5g – CbCBN (mutant) + synaptotagmin-2 + Mg
- 1g9a, 1g9b, 1g9c, 1g9d – CbCBN + inhibitor + Zn
- 1i1e – CbCBN + doxorubicin + Zn
- 1f31 – CbPBN + trisaccharide + Zn
- 7qfq – CbCBN (mutant) – Cryo EM
- Type B Light Chain residues 1-440
- Type B Light+Heavy Chain translocation domain residues 1-858
- Type B receptor-binding domain residues 857-1291
- Type C Light Chain
- Type C receptor-binding domain
- Type D Light Chain
- 2fpq - CbCBN LC + Zn
- 2fpq - CbCBN LC + Zn
- Type D receptor-binding domain
- Type D LHN domain
- 5bqn - CbCBN
- 5bqn - CbCBN
- Type DC Heavy Chain
- Type E
- Type E Light Chain
- Type E heavy Chain
- 7uie – CbCBN HC + synaptic vesicle glycoprotei
- 7uie – CbCBN HC + synaptic vesicle glycoprotei
- Type F Light Chain
- Type F receptor-binding domain
- Type G Light Chain
- 1zb7 - CbCBN LC + Zn
- 1zb7 - CbCBN LC + Zn
- Type G receptor-binding domain
- Type H Light Chain
- 6bvd - CbCBN LC + Zn
- 6bvd - CbCBN LC + Zn
- Type X Light Chain
- Type X
- 8qft - CbCBN
- 8qft - CbCBN